Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As part of World Cancer Day 2022 we are diving into 10 of Oxford’s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.

Radcliffe Library and  woman at a machine in a lab

1. Uncovering the significance of hypoxia in cancer science

A discovery so significant that it warranted a Nobel prize: Sir Peter Ratcliffe is famed for his work on oxygen deprivation (hypoxia) and subsequent cellular responses.

Cancers have unique microenvironments, which they must overcome in order to grow rapidly and uncontrollably. By understanding these conditions and how they come about, clinicians and researchers can strive to develop new drugs to reverse or suppress these pathways.

During his time in Oxford’s Nuffield Department of Medicine, Sir Peter discovered that a specific hormone, known as EPO, was involved in the production of blood cells in response to low oxygen levels in the kidneys. The underlying mechanism behind this process was later applied to cancer, and explained how cancers could create new blood vessels to sustain their fast and uncontrolled growth. This discovery was so significant, he was awarded the Nobel Prize in Medicine in 2019. Ratcliffe’s work into EPO has paved the way for the development of new drugs to improve the efficacy of cancer treatments.

NOW: Continuing this important work into tumour microenvironments, the Oxford ARCADIAN project is now investigating how common antimalarial drug Atovaquone can help to reduce the hypoxic environment of tumours and improve the efficacy of treatments such as radiation. 

 Read the full story on the Oxford Cancer website. 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.